Stockreport

Rhythm Pharmaceuticals Announces ?IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF -- Health Canada accepts for review new drug submission for setmelanotide for the treatment of obesity and control of hunger in BBS and biallelic POMC, PCSK1 and LEPR de [Read more]